Coalition aims to double CAR-T therapy access by 2030

By Drug Discovery World

July 1, 2025 – CAR T Vision has launched to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR-T therapy.

By 2030, the coalition aims to double the proportion of eligible patients treated with CAR-T therapy.  

As outlined in a new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR-T healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR-T; expanding resources and capacity to deliver CAR-T; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. 

“Despite CAR-T therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perales, Chief, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center (MSK); Past President, American Society for Transplantation and Cellular Therapy (ASTCT); and CAR T Vision Steering Committee Co-Chair.  

“When it comes to treating these potentially deadly cancers, every minute counts. That is why we established CAR T Vision with recommendations for interventions that, when adopted and scaled, will help many more eligible patients get the opportunity for cure within the next five years.”

A roadmap to action

The roadmap report, developed by an independent Steering Committee, provides the foundations for advocacy and action by local stakeholders to address the specific access challenges patients face in different geographies.

Building on the report, expert Working Groups will be established to translate the Vision into concrete, measurable actions, including specific recommendations and a measurement framework to track progress.

“Limited awareness of CAR-T therapy, low referrals, hospital capacity challenges, and funding and reimbursement are among the barriers that either prevent people from accessing CAR-T therapy altogether or cause delays that advance a patient’s cancer beyond the point of treatment eligibility. In short, these barriers cost lives,” said Anna Sureda, Clinical Hematologist, Professor and Cell Therapy Researcher; and CAR T Vision Steering Committee Co-Chair. “We call on every stakeholder and organisation with the ability to help shape better patient outcomes—policymakers, health system leaders, payors, healthcare providers, patient advocates, and industry—to join the growing coalition of Vision endorsers and help ensure every eligible patient has the opportunity for cure with CAR-T therapy.”